|
Volumn 19, Issue 3, 2005, Pages 216-219
|
A field trial of recombinant human interferon alpha-2b for nasal spray to prevent SARS and other respiratory viral infections
a a a a a a a a a a a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
ALPHA2B INTERFERON;
ANTIVIRUS AGENT;
IMMUNOGLOBULIN G;
IMMUNOGLOBULIN M;
VIRUS ANTIBODY;
ADULT;
ARTICLE;
BLOOD;
CHEMICALLY INDUCED DISORDER;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOUBLE BLIND PROCEDURE;
DRUG EFFECT;
HUMAN;
IMMUNOLOGY;
INTRANASAL DRUG ADMINISTRATION;
RANDOMIZED CONTROLLED TRIAL;
RESPIRATORY TRACT INFECTION;
SARS CORONAVIRUS;
SEVERE ACUTE RESPIRATORY SYNDROME;
TREATMENT OUTCOME;
VIROLOGY;
ADMINISTRATION, INTRANASAL;
ADULT;
ANTIBODIES, VIRAL;
ANTIVIRAL AGENTS;
DOUBLE-BLIND METHOD;
HUMANS;
IMMUNOGLOBULIN G;
IMMUNOGLOBULIN M;
INTERFERON ALFA-2B;
RESPIRATORY TRACT INFECTIONS;
SARS VIRUS;
SEVERE ACUTE RESPIRATORY SYNDROME;
TREATMENT OUTCOME;
YOUNG ADULT;
|
EID: 58149216877
PISSN: 10039279
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
Times cited : (12)
|
References (0)
|